HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

AuthorsJared R Adams, Cara Angelotta, Charles L Bennett
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 24 Issue 19 Pg. 2975-7 (Jul 01 2006) ISSN: 1527-7755 [Electronic] United States
PMID16682722 (Publication Type: Comment, Editorial)
Chemical References
  • Antineoplastic Agents
  • Granulocyte Colony-Stimulating Factor
Topics
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Cost-Benefit Analysis
  • Fever (chemically induced, economics, prevention & control)
  • Granulocyte Colony-Stimulating Factor (economics, therapeutic use)
  • Humans
  • Neutropenia (chemically induced, economics, prevention & control)
  • Practice Guidelines as Topic
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: